A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

This study is testing a new cell therapy called SCG101 for people with liver cancer (hepatocellular carcinoma) that is related to chronic hepatitis B virus infection. SCG101 uses the patient's own modified immune cells to target and attack cancer cells that carry the hepatitis B virus. **You may be eligible if...** - You have been diagnosed with liver cancer confirmed by biopsy or imaging - Your liver cancer is related to hepatitis B virus (HBsAg positive) - You have already received at least 2 prior systemic treatments that have not worked - You have a specific immune system marker (HLA-A*02) - Your liver function and overall health are adequate **You may NOT be eligible if...** - You have cancer that has spread widely or your liver function is severely impaired - You have active hepatitis C or HIV - You have uncontrolled fluid in the abdomen or bleeding from the digestive tract - You have had a prior organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.